In Vitro Growth Inhibition, Caspase-Dependent Apoptosis, and S and G2/M Phase Arrest in Breast Cancer Cells Induced by Fluorine-Incorporated Gold I Compound, Ph3PAu[SC(OMe)=NC6H4F-3].

IF 1.6 Q4 ONCOLOGY International Journal of Breast Cancer Pub Date : 2022-07-21 eCollection Date: 2022-01-01 DOI:10.1155/2022/7168210
Richard Ming Chuan Yu, Gayathri Thevi Selvarajah, Geok Chin Tan, Yoke-Kqueen Cheah
{"title":"<i>In Vitro</i> Growth Inhibition, Caspase-Dependent Apoptosis, and S and G2/M Phase Arrest in Breast Cancer Cells Induced by Fluorine-Incorporated Gold I Compound, Ph3PAu[SC(OMe)=NC6H4F-3].","authors":"Richard Ming Chuan Yu,&nbsp;Gayathri Thevi Selvarajah,&nbsp;Geok Chin Tan,&nbsp;Yoke-Kqueen Cheah","doi":"10.1155/2022/7168210","DOIUrl":null,"url":null,"abstract":"<p><p>Gold-based anticancer compounds have been attracting increasing research interest due to their ability to kill cancer cells resistant to platinum-based compounds. Gold I- and gold III-based complexes have shown satisfactory anticancer activities. In this study, two new fluorine-incorporated gold (I) compounds such as Ph<sub>3</sub>PAu[SC(OMe)=NC<sub>6</sub>H<sub>4</sub>F-3] and DPPFeAu<sub>2</sub>[(SC(OMe)=NC<sub>6</sub>H<sub>4</sub>F-3)]<sub>2</sub> were evaluated for their <i>in vitro</i> activities against human breast cancer cell lines, primary breast cancer cells, and breast cancer stem cells (parental breast cancer stem cells, BCSC-P, and breast cancer stem cells, BCSC). Assays for growth inhibition and cytotoxicity, including real-time cell analysis, were carried out to screen effective antibreast cancer compounds. In addition, further <i>in vitro</i> assays such as apoptosis, caspase 3/7 activity, and cell cycle analysis were performed to observe the action and mechanism of killing breast cancer cells by the selected gold I compound, Ph<sub>3</sub>PAu[SC(OMe)=NC<sub>6</sub>H<sub>4</sub>F-3]. The gold (I) compound, Ph<sub>3</sub>PAu[SC(OMe)=NC<sub>6</sub>H<sub>4</sub>F-3], showed low toxicity to H9c2 normal cells and significant growth inhibition in MDA-MB-231 and MCF-7 cells, primary breast cancer cells, and breast cancer stem cells (BCSC-P and BCSC). The IC<sub>50</sub> doses of the gold (I) compound Ph<sub>3</sub>PAu[SC(OMe)=NC<sub>6</sub>H<sub>4</sub>F-3] against the breast cancer cell lines MDA-MB-231 and MCF-7 were approximately 6-fold lower than that of cisplatin (cis-diamineplatinum (II) dichloride, CDDP). Moreover, the compound Ph<sub>3</sub>PAu[SC(OMe)=NC<sub>6</sub>H<sub>4</sub>F-3] induced caspase 3/7-dependent apoptosis and cell cycle arrest at S and G2/M phases. Ph<sub>3</sub>PAu[SC(OMe)=NC<sub>6</sub>H<sub>4</sub>F-3], a gold (I) compound incorporated with fluorine, is a potential candidate for the treatment of breast cancer.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2022-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334116/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Breast Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2022/7168210","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Gold-based anticancer compounds have been attracting increasing research interest due to their ability to kill cancer cells resistant to platinum-based compounds. Gold I- and gold III-based complexes have shown satisfactory anticancer activities. In this study, two new fluorine-incorporated gold (I) compounds such as Ph3PAu[SC(OMe)=NC6H4F-3] and DPPFeAu2[(SC(OMe)=NC6H4F-3)]2 were evaluated for their in vitro activities against human breast cancer cell lines, primary breast cancer cells, and breast cancer stem cells (parental breast cancer stem cells, BCSC-P, and breast cancer stem cells, BCSC). Assays for growth inhibition and cytotoxicity, including real-time cell analysis, were carried out to screen effective antibreast cancer compounds. In addition, further in vitro assays such as apoptosis, caspase 3/7 activity, and cell cycle analysis were performed to observe the action and mechanism of killing breast cancer cells by the selected gold I compound, Ph3PAu[SC(OMe)=NC6H4F-3]. The gold (I) compound, Ph3PAu[SC(OMe)=NC6H4F-3], showed low toxicity to H9c2 normal cells and significant growth inhibition in MDA-MB-231 and MCF-7 cells, primary breast cancer cells, and breast cancer stem cells (BCSC-P and BCSC). The IC50 doses of the gold (I) compound Ph3PAu[SC(OMe)=NC6H4F-3] against the breast cancer cell lines MDA-MB-231 and MCF-7 were approximately 6-fold lower than that of cisplatin (cis-diamineplatinum (II) dichloride, CDDP). Moreover, the compound Ph3PAu[SC(OMe)=NC6H4F-3] induced caspase 3/7-dependent apoptosis and cell cycle arrest at S and G2/M phases. Ph3PAu[SC(OMe)=NC6H4F-3], a gold (I) compound incorporated with fluorine, is a potential candidate for the treatment of breast cancer.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
含氟金I化合物Ph3PAu诱导乳腺癌细胞体外生长抑制、caspase依赖性凋亡及S和G2/M期阻滞[SC(OMe)=NC6H4F-3]。
金基抗癌化合物由于能够杀死抵抗铂基化合物的癌细胞而引起了越来越多的研究兴趣。金I和金iii基配合物显示出令人满意的抗癌活性。本研究对两种新型含氟金(I)化合物Ph3PAu[SC(OMe)=NC6H4F-3]和DPPFeAu2[(SC(OMe)=NC6H4F-3)]2对人乳腺癌细胞系、原发性乳腺癌细胞和乳腺癌干细胞(亲代乳腺癌干细胞BCSC- p和乳腺癌干细胞BCSC)的体外活性进行了评价。进行生长抑制和细胞毒性试验,包括实时细胞分析,以筛选有效的抗乳腺癌化合物。此外,通过细胞凋亡、caspase 3/7活性、细胞周期分析等体外实验,观察筛选出的金I化合物Ph3PAu[SC(OMe)=NC6H4F-3]杀伤乳腺癌细胞的作用及机制。金(I)化合物Ph3PAu[SC(OMe)=NC6H4F-3]对H9c2正常细胞具有低毒性,对MDA-MB-231和MCF-7细胞、原发性乳腺癌细胞和乳腺癌干细胞(BCSC- p和BCSC)具有显著的生长抑制作用。金(I)化合物Ph3PAu[SC(OMe)=NC6H4F-3]对乳腺癌细胞株MDA-MB-231和MCF-7的IC50剂量比顺铂(顺二胺铂(II)二氯化,CDDP)低约6倍。此外,化合物Ph3PAu[SC(OMe)=NC6H4F-3]在S期和G2/M期诱导caspase 3/7依赖性细胞凋亡和细胞周期阻滞。Ph3PAu[SC(OMe)=NC6H4F-3]是一种与氟结合的金(I)化合物,是治疗乳腺癌的潜在候选物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.40
自引率
0.00%
发文量
25
审稿时长
19 weeks
期刊介绍: International Journal of Breast Cancer is a peer-reviewed, Open Access journal that provides a forum for scientists, clinicians, and health care professionals working in breast cancer research and management. The journal publishes original research articles, review articles, and clinical studies related to molecular pathology, genomics, genetic predisposition, screening and diagnosis, disease markers, drug sensitivity and resistance, as well as novel therapies, with a specific focus on molecular targeted agents and immune therapies.
期刊最新文献
PI3K Mutation Profiles on Exons 9 (E545K and E542K) and 20 (H1047R) in Mexican Patients With HER-2 Overexpressed Breast Cancer and Its Relevance on Clinical-Pathological and Survival Biological Effects. Factors Associated With Uptake of Breast Cancer Screening Among Catholic Nuns in Lake Zone, Tanzania. Triple-Negative Breast Cancer: Tumor Immunogenicity and Beyond. Assessing Awareness, Attitude, and Practices of Breast Cancer Screening and Prevention Among General Public and Physicians in Pakistan: A Nation With the Highest Breast Cancer Incidence in Asia. Assessment of Tissue Eosinophilic Infiltration in Invasive Mammary Carcinoma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1